{{Rsnum
|rsid=1799732
|Gene=DRD2
|Chromosome=11
|position=113475529
|Orientation=plus
|GMAF=0.2346
|Gene_s=DRD2
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(-;-)
|geno2=(-;C)
|geno3=(C;C)
}}[[rs1799732]] is a SNP in the D2 dopamine receptor gene [[DRD2]] gene. Although dbSNP indicates the alleles as (C) or (-) (i.e. a deletion), investigators report the alleles as (C) or (T).

In a study of individuals in the Polyp Prevention Trial with any, multiple (>/=2) or advanced colorectal adenoma recurrence after 4 years, compared to those without adenoma recurrence, [[rs1799732]](C;T) individuals were significantly associated with all adenoma recurrence (odds ratio 1.30, CI: 1.01-1.69).  The authors speculate this increased risk of adenoma recurrence (and an association with [[colorectal cancer]]) may be related to SNP-associated differences in alcohol and fat intake.{{PMID| 19065655|OA=1
}}

[http://blog.23andme.com/2009/09/22/snpwatch-evidence-for-gene-environment-interaction-in-alcoholism/ 23andMe blog] Alcoholism related
*[[rs1799971]](A;A) severe alcoholism 2x 
*[[rs1799732]](I;I) severe alcoholism 1.85x

{{PMID Auto
|PMID=19373123
|Title=Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution
}}

{{PMID Auto
|PMID=19547807
|Title=Association between the DRD2-141C Insertion/Deletion polymorphism and schizophrenia
}}

{{PharmGKB
|RSID=rs1799732
|Name_s=DRD2: -141C Ins/Del
|Gene_s=DRD2
|Feature=
|Evidence=PubMed ID:16513877
|Annotation=Risk or phenotype-associated allele: Del. Phenotype: Carriers of the -141C Del allele showed significantly longer time to respond to the antipsychotics relative to the Ins/Ins homozygous patients (p<0.03). Study size: 61 patients experiencing their first episode of schizophrenia. Study population: 41% African American; 28% Caucasian (European); 18% Hispanic; 5% Asian; 8% other.
|Drugs=olanzapine; risperidone
|Drug Classes=
|Diseases=Schizophrenia
|Curation Level=Curated
|PharmGKB Accession ID=PA165291672
}}

{{PMID Auto
|PMID=19512960
|Title=Genetic diagnostics of functional variants of the human dopamine D2 receptor gene
}}

{{PMID Auto
|PMID=20664489
|Title=DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia
|OA=1
}}

{{PharmGKB
|RSID=rs1799732
|Name_s=DRD2:-141C Ins/Del
|Gene_s=DRD2
|Feature=
|Evidence=Web Resource:http://www.pharmgkb.org/search/annotatedGene/drd2/variant.jsp
|Annotation=May have a role in determining the response to antipsychotic drugs in schizophrenic inpatients; in schizophrenic patients, the Del allele of the -141C Ins/Del DRD2 polymorphism is associated with a less favorable clinical outcome on antipsychotic therapy than the Ins allele.
|Drugs=
|Drug Classes=ANTIPSYCHOTICS
|Diseases=Schizophrenia
|Curation Level=In-Depth
|PharmGKB Accession ID=PA161145171
}}

{{PharmGKB
|RSID=rs1799732
|Name_s=DRD2: -141C Ins/Del
|Gene_s=DRD2
|Feature=
|Evidence=PubMed ID:15694263
|Annotation=Phenotype: The &#8722;141C Ins/Del polymorphism was found to be significantly related to the therapeutic effect of chlorpromazine in schizophrenia patients (P = 0.01). Patients with no Del allele showed greater improvement than those with Del allele on the overall Brief Psychiatry Rating Scale (P=0.03). For the TaqI A SNP (rs1800497) no significant difference in genotype was observed between drug responder and non-responder groups (P = 0.99). Study size: 135 inpatients. Study population: Chinese.
|Drugs=chlorpromazine
|Drug Classes=
|Diseases=Schizophrenia
|Curation Level=Curated
|PharmGKB Accession ID=PA165291670
}}

{{PharmGKB
|RSID=rs1799732
|Name_s=DRD2: -141C Ins/Del
|Gene_s=DRD2
|Feature=
|Evidence=PubMed ID:9918131
|Annotation=Phenotype: No association was found between the -141C Ins/Del polymorphism and clinical response to clozapine in 151 schizophrenic patients of British origin. Study size: 151 schizophrenics; 95 controls. Study population: Caucasian.
|Drugs=clozapine
|Drug Classes=
|Diseases=Schizophrenia
|Curation Level=Curated
|PharmGKB Accession ID=PA165291666
}}

{{PharmGKB
|RSID=rs1799732
|Name_s=DRD2: -141C Ins/Del
|Gene_s=DRD2
|Feature=
|Evidence=PubMed ID:11505224
|Annotation=Risk or phenotype-associated allele: Del of -141C. Phenotype: The patients without Del allele showed a higher percentage of improvement in anxiety-depression symptoms than those with Del allele (58.5 &#177; 44.5% versus 24.1 &#177; 48.2%, P = 0.037) but no association was found for other symptoms of the Brief Psychiatric Rating Scale. Study size: 30 schizophrenic inpatients treated with bromperidol; 19 schizophrenic inpatients treated with nemonapride. Study population: Japanese.
|Drugs=Bromperidol; nemonapride
|Drug Classes=
|Diseases=Schizophrenia
|Curation Level=Curated
|PharmGKB Accession ID=PA165291668
}}

{{PharmGKB
|RSID=rs1799732
|Name_s=DRD2: -141C Ins/Del
|Gene_s=DRD2
|Feature=
|Evidence=PubMed ID:15830237
|Annotation=Phenotype: No association was found between the -141C Ins/Del polymorphism and clozapine response in either the Caucasian or African-American population sample. Study size and population: 183 Caucasian and 49 African-American.
|Drugs=clozapine
|Drug Classes=
|Diseases=Schizophrenia
|Curation Level=Curated
|PharmGKB Accession ID=PA165291671
}}

{{PharmGKB
|RSID=rs1799732
|Name_s=DRD2: -141C Ins/Del
|Gene_s=DRD2
|Feature=
|Evidence=PubMed ID:16123753
|Annotation=A double-blind placebo-controlled trial of bupropion (n=414) found a statistically significant interaction of the - 141C Ins/Del genotype with the bupropion treatment group (OR=4.99; 95% CI=1.42, 17.62; p=0.01). Bupropion was more effective for patients who were homozygous for the Ins allele. In an open label trial of transdermal nicotine vs nicotine nasal spray (n=368), the participants with Ins/Ins genotypes were about one-half as likely to be abstinent at the end of treatment as participants with Ins/Del or Del/Del genotypes (OR=0.44; CI=0.25, 0.79; p=0.006).
|Drugs=bupropion
|Drug Classes=
|Diseases=Tobacco Use Disorder
|Curation Level=Curated
|PharmGKB Accession ID=PA165291680
}}

{{PharmGKB
|RSID=rs1799732
|Name_s=DRD2: -141C Ins/Del
|Gene_s=DRD2
|Feature=
|Evidence=PubMed ID:20194480
|Annotation=Phenotype: Results of this meta-analysis showed that the group of Del allele carrier was significantly associated with poorer antipsychotic drug response relative to the Ins/Ins genotype. Study size: meta-analysis included six individual studies, 687 patients total.
|Drugs=aripiprazole; chlorpromazine; clozapine; olanzapine; risperidone
|Drug Classes=
|Diseases=Schizophrenia
|Curation Level=Curated
|PharmGKB Accession ID=PA165291678
}}

{{PharmGKB
|RSID=rs1799732
|Name_s=DRD2: -141C Ins/Del
|Gene_s=DRD2
|Feature=
|Evidence=PubMed ID:19603545
|Annotation=Phenotype: In this case-control study the polymorphisms -141C Ins/Del (rs1799732); C957T (rs6277); A1385G (rs6276); and TaqIA (rs1800497) were genotyped. The haplotypes I-C-G-A2 and I-C-A-A1 occurred with a higher frequency in alcoholics [P=0.026, odds ratio (OR): 1.340; P=0.010, OR: 1.521, respectively]. Study size: 360 alcoholics and 368 controls. Study population:Caucasian individuals of German origin.
|Drugs=ethanol
|Drug Classes=
|Diseases=Alcoholism
|Curation Level=Curated
|PharmGKB Accession ID=PA165291686
}}

{{PharmGKB
|RSID=rs1799732
|Name_s=DRD2: -141C Ins/Del
|Gene_s=DRD2
|Feature=
|Evidence=PubMed ID:9858029
|Annotation=Phenotype: No association was found between the-141C Ins/Del polymorphism and the response to antipsychotic medication in 170 schizophrenics and 121 healthy control subjects. But the frequency of the Ins allele was significantly increased in the schizophrenics compared with the control subjects (P = 0.042). Study size: 170 schizophrenics and 121 healthy controls. Study population: Japanese.
|Drugs=
|Drug Classes=ANTIPSYCHOTICS
|Diseases=Schizophrenia
|Curation Level=Curated
|PharmGKB Accession ID=PA165291667
}}

{{PharmGKB
|RSID=rs1799732
|Name_s=DRD2: -141C Ins/Del
|Gene_s=DRD2
|Feature=
|Evidence=PubMed ID:14610521
|Annotation=Risk or phenotype-associated genotype: Ins-A2/Ins-A2 diplotype. Phenotype: DRD2 Ins-A2/Del-A1 diplotype (n=10) compared with Ins-A2/Ins-A2 (n=25) diplotype may predict superior risperidone response in schizophrenic patients. Positive and Negative Syndrome Scale total scores of patients with Ins-A2/Del-A1 diplotype showed 40% greater improvement (P=0.03). Patients with other diplotypes did not differ significantly in any subscale scores or the total score. -141C Ins/Del (rs1799732); Taq1A (rs1800497; C32806T). Study size: 73 patients with schizophrenia. Study population: Japanese.
|Drugs=risperidone
|Drug Classes=
|Diseases=Schizophrenia
|Curation Level=Curated
|PharmGKB Accession ID=PA165291669
}}

{{PharmGKB
|RSID=rs1799732
|Name_s=DRD2: -141C Ins/Del
|Gene_s=DRD2
|Feature=
|Evidence=PubMed ID:17105675
|Annotation=Phenotype: No association was found between the -141C Ins/Del polymorphism and response to risperidone. Study size: 125. Study population: Chinese.
|Drugs=risperidone
|Drug Classes=
|Diseases=Schizophrenia
|Curation Level=Curated
|PharmGKB Accession ID=PA165291673
}}

{{PharmGKB
|RSID=rs1799732
|Name_s=DRD2: -141C Ins/Del
|Gene_s=DRD2
|Feature=
|Evidence=PubMed ID:18926547
|Annotation=Phenotype: After 4-week aripiprazole treatment the &#8722;141C Ins/Del polymorphism had no significant effects on the positive and negative syndrome scale performance. Study size:128 schizophrenic patients. Study population: Chinese.
|Drugs=aripiprazole
|Drug Classes=
|Diseases=Schizophrenia
|Curation Level=Curated
|PharmGKB Accession ID=PA165291675
}}

{{PMID Auto
|PMID=21714067
|Title=Association between polymorphisms of DRD2 and DRD4 and opioid dependence: Evidence from the current studies
}}

{{PMID Auto
|PMID=17135598
|Title=No evidence for a major role of polymorphisms during bupropion treatment.
}}

{{PMID Auto
|PMID=17417059
|Title=A dopamine D2 receptor gene-related polymorphism is associated with schizophrenia in a Spanish population isolate.
}}

{{PMID Auto
|PMID=17466074
|Title=Genetic polymorphisms in dopamine-related genes and smoking cessation in women: a prospective cohort study.
|OA=1
}}

{{PMID Auto
|PMID=18077373
|Title=Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory.
|OA=1
}}

{{PMID Auto
|PMID=18305461
|Title=Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety.
|OA=1
}}

{{PMID Auto
|PMID=18366720
|Title=Association of dopaminergic pathway gene polymorphisms with chronic renal insufficiency among Asian Indians with type-2 diabetes.
|OA=1
}}

{{PMID Auto
|PMID=18563706
|Title=The impact of genetic variation in DRD2 and SLC6A3 on smoking cessation in a cohort of participants 1 year after enrollment in a lung cancer screening study.
|OA=1
}}

{{PMID Auto
|PMID=18715757
|Title=Genetic associations with schizophrenia: meta-analyses of 12 candidate genes.
|OA=1
}}

{{PMID Auto
|PMID=19285111
|Title=C957T polymorphism of the human dopamine D2 receptor gene predicts extrastriatal dopamine receptor availability in vivo.
}}

{{PMID Auto
|PMID=19390575
|Title=Lung cancer susceptibility model based on age, family history and genetic variants.
|OA=1
}}

{{PMID Auto
|PMID=19669131
|Title=Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease.
|OA=1
}}

{{PMID Auto
|PMID=20146828
|Title=Dopamine D2 receptor polymorphisms and susceptibility to alcohol dependence in Indian males: a preliminary study.
|OA=1
}}

{{PMID Auto
|PMID=20191112
|Title=The Genetics of Anorexia Nervosa: Current Findings and Future Perspectives.
|OA=1
}}

{{PMID Auto
|PMID=21162693
|Title=Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.
|OA=1
}}

{{PMID Auto
|PMID=21554498
|Title=Dopaminergic genes modulate response inhibition in alcohol abusing adults.
}}

{{PMID Auto
|PMID=21645585
|Title=Resting posterior minus frontal EEG slow oscillations is associated with extraversion and DRD2 genotype.
}}

{{PMID Auto
|PMID=22382052
|Title=A DRD2 and ANKK1 haplotype is associated with nicotine dependence.
}}

{{PMID Auto
|PMID=22574669
|Title=Dopamine receptors D1 and D2 are related to observed maternal behavior.
}}

{{PMID Auto
|PMID=22615781
|Title=Candidate gene-based association study of antipsychotic-induced movement disorders in long-stay psychiatric patients: a prospective study
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1799732
|overall_frequency_n=36
|overall_frequency_d=124
|overall_frequency=0.290323
|n_genomes=27
|n_genomes_annotated=0
|n_haplomes=48
|n_articles=12
|n_articles_annotated=7
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=22579533
|Title=Binge eating disorder and the dopamine D2 receptor: genotypes and sub-phenotypes.
}}

{{PMID Auto
|PMID=22875483
|Title=Identification of a novel ANKK1 and other dopaminergic (DRD2 and DBH) gene variants in migraine susceptibility.
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}